Loading clinical trials...

UNKNOWNPHASE1/PHASE2

Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents

The Addition of rTMS to the Therapy of Adolescents That Suffer From Treatment Resistant Depression: An Open Label Study

NCT01170520•Shalvata Mental Health Center

Summary

The investigators hypothesis that repetitive transcranial Stimulation (rTMS) is a safe and effective add-on therapy for resistent depression in adolescent patients. A group of adolescents suffering from non psychotic major depression that was resistant to at least 2 drug trials and a trail of psychotherapy will be recruited. After an informed consent procedure for both parents and patients, patients will go through a clinical and cognitive evaluation. They will receive a protocol of 4 weeks (20 work days) of rTMS using the figure of 8 magstim coil at 100% threshold, 42 trains of 4 seconds each, intertrain interval of 30 sec to the LDPC, 1680 pulses per day. Then they will be reevaluated.

Eligibility

Age

15 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 15-18 years old
•Right hand dominant
•Suffering from major depression
•CDRS \> 60
•At least 3 months of current depressive episode
•Failed 2 drug trials (or 3 drug trials if trial terminated prematurely due to side effects) and at least 1 course of psychotherapy
•No contraindication for rtms (safety questionnaire)
•No change in pharmacotherapy in the last month

Exclusion Criteria

•Schizophrenia or psychotic symptoms
•Hypertension
•Epilepsy
•History of major head trauma
•Metal implements in the head
•History of neurosurgery
•History of severe head migraine
•History of hearing loss or sp cochlear transplantation
•Pregnancy
•Current drug abuse
+3 more criteria

Locations (2)

Shalvata Mental health Center

Hod HaSharon, Israel

Shalvata Mental Health Center

Hod HaSharon, Israel

Key Dates

Start Date

August 1, 2010

Primary Completion Date

September 1, 2013

Last Updated

January 5, 2012

Enrollment

ESTIMATED participants

Conditions

Adolescent Depression

Interventions

repetitive transcranial Stimulation

DEVICE

Contacts

Yuval Bloch, MD

CONTACT

972-506264628 yuvalbl@clalit.org.il; aviva100@bezeqint.net

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

NCT04613453

Adolescent SuicideAdolescent Depression

View study

COMPLETEDNA

Predictors of Response to Treatment for Depression

NCT03154008

Adolescent DepressionDepression

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 5, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents

Inclusion Criteria

Exclusion Criteria

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Predictors of Response to Treatment for Depression

Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study

Lamotrigine in Treatment Resistant Depression in Adolescents

Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy